(Q40018367)

English

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo

scientific article published on 31 January 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Stacey A Taylor

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Cindy H Marrinan

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Gongjie Liu

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Lissette Nale

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

W Robert Bishop

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Paul Kirschmeier

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Ming Liu

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Brian J Long

8

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

language of work or name

0 references

publication date

31 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

109

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

97-106

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Ovarian cancer: epidemiology, biology, and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Lipid posttranslational modifications. Farnesyl transferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Ovarian cancer: strategies for overcoming resistance to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.12.013

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.12.013

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40018367&oldid=1882678639"